Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Analysis of >12,000 SB integration sites revealed markedly different oncogene activations in EL and T-ALL: Notch1 and Ikaros were most common in T-ALL, whereas ETS transcription factors (Erg and Ets1) were targeted in most ELs.
|
30940846 |
2019 |
Lymphoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The frequency of NOTCH1 variants in T-acute lymphoblastic leukemia/lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma among Jordanian patients.
|
30718223 |
2019 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Recurrent mutations in NF-κB pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.
|
27566587 |
2016 |
Lymphoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Oncogenic mutations in NOTCH1 are common in human T-cell leukemia and lymphomas.
|
24525741 |
2014 |
Lymphoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), activating mutations of NOTCH1 are observed in more than 50% of cases, whereas the t(7;9)(q34;q34) involving NOTCH1 at 9q34 and TRB@ at 7q34 is an extremely rare but recurrent translocation.
|
23033986 |
2013 |
Lymphoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The lymphomas arise from developing T cells, and contain activated Notch1, similar to most human and mouse T-cell acute lymphoblastic lymphomas.
|
20956329 |
2010 |
Lymphoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1.
|
17874453 |
2008 |
Lymphoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Dideoxycytidine-induced lymphomas displayed the highest frequency of Notch1 mutations (49%), whereas in butadiene- and phenolphthalein-induced tumors showed lower frequencies (26 and 10%, respectively).
|
18798262 |
2008 |
Lymphoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Seven out of 16 hypomethylation-induced lymphomas were found to contain an intracisternal A particle (IAP) somatic insertion in the middle of the Notch1 genomic locus, leading to generation of an oncogenic form of Notch1 in the tumors.
|
17621273 |
2008 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas.
|
18765521 |
2008 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Although NOTCH1 mutation occurs infrequently in mature T-cell leukemia/lymphoma, NOTCH1 may be involved in leukemogenesis associated with various forms of T-cell leukemia/lymphoma rather than only with T-ALL.
|
17483057 |
2007 |
Lymphoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In contrast, lymphomas arising in p53(-/-) mice show the activation of Notch1, but no mutations were identified in ICN.
|
16449526 |
2006 |
Lymphoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In addition, we found activating Notch1 mutations in 31% of thymic lymphomas that occur in mice deficient for various combinations of the H2AX, Tp53, and Rag2 genes.
|
16166587 |
2006 |
Lymphoma
|
0.400 |
Biomarker
|
group |
LHGDN |
In contrast, lymphomas arising in p53(-/-) mice show the activation of Notch1, but no mutations were identified in ICN.
|
16449526 |
2006 |
Lymphoma
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Deregulated NOTCH signaling in acute T-cell lymphoblastic leukemia/lymphoma: new insights, questions, and opportunities.
|
16298817 |
2005 |
Lymphoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Three human disorders including a neoplasia (a T-cell acute lymphoblastic leukemia/lymphoma), a late onset neurological disease (CADASIL) and a developmental disorder (the Alagille syndrome) are associated with mutations in, respectively, the Notch1, Notch3 and Jagged1 genes, pointing out the broad spectrum of Notch activity in humans.
|
10075489 |
1998 |